Oct. 4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

This includes very encouraging results with a new drug, teclistamab (Tecvayli™), which he shepherded through clinical trials to its approval by the Food and Drug Administration (FDA). Multiple myeloma ...

Multiple myeloma (MM) is a B-cell malignancy characterized ... As the distribution of the clinical parameters and the percentage of MYC staining cells was not statistically different between ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple ...

Survival of patients with multiple myeloma (MM) has markedly improved over ... Supported in part by a Jacquelin Forbes-Nixon Fellowship (to M.F.K.) via Myeloma UK and by Core Clinical Trials Unit ...

Opna Bio, a clinical-stage biopharmaceutical company ... for the treatment of multiple myeloma (MM). OPN-6602 is an oral, small molecule inhibitor of the E1A binding protein (EP300) and CREB ...